Masimo (MASI) | Financial Analysis & Statements

Masimo Corporation | Mid-cap | Healthcare

162,54 US$

0,83 %

| Masimo Stock Comparison:

Masimo vs Abbott Laboratories Masimo vs Boston Scientific Masimo vs Globus Medical Masimo vs Bio-Rad Masimo vs Bio-Rad Laboratories Masimo vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2,1B

Gross Profit 1,0B 47,96 %

Operating Income 37,8M 1,80 %

Net Income -304,9M -14,56 %

EPS (Diluted) -5,72 US$

Balance Sheet Metrics

Total Assets 2,6B

Total Liabilities 1,6B

Shareholders Equity 1,1B

Debt to Equity 1,50

Cash Flow Metrics

Operating Cash Flow -249,5M

Free Cash Flow 145,3M

Revenue & Profitability Trend

Income Statement

Metric	2024	2023	2022	2021	2020
Revenue	2,1B	2,0B	2,0B	1,2B	1,1B
Cost of Goods Sold	1,1B	1,0B	977,0M	430,8M	400,7M
Gross Profit	1,0B	1,0B	1,1B	808,4M	743,0M
Operating Expenses	966,6M	839,2M	848,8M	532,6M	487,7M
Operating Income	37,8M	164,3M	210,0M	275,8M	255,3M
Pre-tax Income	-305,3M	88,1M	193,4M	274,4M	263,7M
Income Tax	-400,0K	6,6M	49,9M	44,8M	23,4M
Net Income	-304,9M	81,5M	143,5M	229,6M	240,3M
EPS (Diluted)	-5,72 US$	1,51 US$	2,60 US$	3,98 US$	4,14 US$

Income Statement Trend

Balance Sheet

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	1,2B	1,2B	1,3B	1,2B	1,1B
Non-Current Assets	1,4B	1,8B	1,9B	648,1M	611,4M
Total Assets	2,6B	3,0B	3,2B	1,9B	1,7B
Liabilities
Current Liabilities	617,7M	563,8M	630,0M	267,7M	233,8M
Non-Current Liabilities	956,1M	1,1B	1,2B	69,1M	71,1M
Total Liabilities	1,6B	1,7B	1,9B	336,8M	304,9M
Equity
Total Shareholders Equity	1,1B	1,4B	1,3B	1,6B	1,4B

Balance Sheet Composition

Cash Flow Statement

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	-304,9M	81,5M	143,5M	229,6M	240,3M
Operating Cash Flow	-249,5M	146,9M	49,2M	249,1M	186,9M
Investing Activities
Capital Expenditures	-20,0M	-44,0M	-52,8M	-25,5M	-72,5M
Investing Cash Flow	-20,1M	-37,5M	-1,1B	-28,1M	-75,4M
Financing Activities
Dividends Paid	-	-	-	-	-
Financing Cash Flow	-363,4M	-297,3M	385,0M	-122,4M	-54,3M
Free Cash Flow	145,3M	6,4M	-26,9M	229,7M	131,2M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 129,16

Forward P/E 34,74

Price to Book 9,24

Price to Sales 4,11

PEG Ratio 34,74

Profitability Ratios

Profit Margin -23,25 %

Operating Margin 21,69 %

Return on Equity -25,07 %

Return on Assets 1,32 %

Financial Health

Current Ratio 2,17

Debt to Equity 72,01

Beta 1,19

Per Share Data

EPS (TTM) -5,46 US$

Book Value per Share 17,46 US$

Revenue per Share 39,72 US$

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
masi	8,7B	129,16	9,24	-25,07 %	-23,25 %	72,01
Abbott Laboratories	232,9B	17,38	4,77	30,65 %	31,89 %	27,09
Boston Scientific	147,6B	72,80	6,64	9,50 %	11,58 %	52,16
Globus Medical	8,0B	43,96	1,95	4,63 %	7,39 %	2,27
Bio-Rad	6,8B	-3,83	1,03	-27,52 %	-85,16 %	20,50
Bio-Rad Laboratories	6,2B	-3,47	0,94	-27,52 %	-85,16 %	20,50

Financial data is updated regularly. All figures are in the company's reporting currency.